Education
About Us
Working with TipRanks
Follow Us
Candel Therapeutics (CADL)
NASDAQ:CADL
CADL Stock Chart & Stats
Day’s Range― - ―
52-Week Range$1.53 - $14.60
Previous CloseN/A
Volume524.53K
Average Volume (3M)1.25M
Market Cap
$328.29M
Enterprise Value$221.32M
Total Cash (Recent Filing)-$45.06M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta-0.92
Next Earnings
May 08, 2025EPS Estimate
-0.38Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.75
Shares Outstanding47,235,460
10 Day Avg. Volume980,353
30 Day Avg. Volume1,245,898
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-16.40
P/FCF Ratio0.00
Enterprise Value/Market Cap0.67
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-4.54
Forecast
1Y Price Target
$21.00Price Target Upside202.16% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
---
Candel Therapeutics News
PremiumCompany Announcements
Candel Therapeutics Reports Positive Phase 2a Trial Results
---
Bulls Say, Bears Say
Bulls Say
Clinical Trial ResultsRecent compelling phase 3 results in prostate cancer and encouraging phase 2 data in pancreatic and lung cancer strengthen the clinical profile of CAN-2409.
Market PotentialThe potential peak sales of $1.1 billion for CAN-2409, across large markets like prostate, pancreatic, and lung cancer, indicate significant revenue opportunities.
Partnership And Commercial StrategyThe partnership with IDEA Pharma enhances the potential for quicker ramp to launch, higher peak penetration, and earlier launch/approval of CAN-2409.
Bears Say
Financial NeedsThe company is likely needing additional financing to support larger pivotal trials and potential filings beyond prostate cancer.
Funding RequirementsCandel Therapeutics may face challenges in securing the necessary funds to support the ambitious clinical and commercial plans for CAN-2409.
---
Ownership Overview
21.00% Insiders
4.34% Mutual Funds
19.59% Other Institutional Investors
49.63% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
CADL FAQ
What was Candel Therapeutics’s price range in the past 12 months?
Candel Therapeutics lowest stock price was $1.53 and its highest was $14.60 in the past 12 months.
What is Candel Therapeutics’s market cap?
Candel Therapeutics’s market cap is $328.29M.
When is Candel Therapeutics’s upcoming earnings report date?
Candel Therapeutics’s upcoming earnings report date is May 08, 2025 which is in 40 days.
How were Candel Therapeutics’s earnings last quarter?
Candel Therapeutics released its earnings results on Mar 13, 2025. The company reported -$0.4 earnings per share for the quarter, missing the consensus estimate of -$0.228 by -$0.172.
Is Candel Therapeutics overvalued?
According to Wall Street analysts Candel Therapeutics’s price is currently Undervalued.
Does Candel Therapeutics pay dividends?
Candel Therapeutics does not currently pay dividends.
What is Candel Therapeutics’s EPS estimate?
Candel Therapeutics’s EPS estimate is -0.38.
How many shares outstanding does Candel Therapeutics have?
Candel Therapeutics has 47,235,460 shares outstanding.
What happened to Candel Therapeutics’s price movement after its last earnings report?
Candel Therapeutics reported an EPS of -$0.4 in its last earnings report, missing expectations of -$0.228. Following the earnings report the stock price went up 10.202%.
Which hedge fund is a major shareholder of Candel Therapeutics?
Currently, no hedge funds are holding shares in CADL
---
Candel Therapeutics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$21.00 (202.16% Upside)
$21.00 (202.16% Upside)
Blogger Sentiment
Neutral
CADL Sentiment 50%
Sector Average 69%
Sector Average 69%
Insider Transactions
Sold Shares
Worth $1.1M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▲ 1.3%
Last 30 Days ▼ 9.2%
Last 30 Days ▼ 9.2%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
351.29%
12-Months-Change
Fundamentals
Return on Equity
-139.56%
Trailing 12-Months
Asset Growth
156.93%
Trailing 12-Months
Company Description
Candel Therapeutics
Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients. The company develops CAN-2409, which is in Phase II clinical trails for the treatment of pancreatic cancer; Phase III clinical trials for the treatment of prostate cancer; and Phase II clinical trials for the treatment of lung cancer, as well as has completed Phase Ib/II clinical trials for the treatment of high-grade glioma. It also develops CAN-3110, which is in Phase I clinical trials for the treatment of recurrent glioblastoma. The company was formerly known as Advantagene, Inc. and changed its name to Candel Therapeutics, Inc. in November 2020. The company was incorporated in 2003 and is based in Needham, Massachusetts.
---
CADL Stock 12 Month Forecast
Average Price Target
$21.00
▲(202.16% Upside)
Technical Analysis
Best Analysts Covering CADL
1 Year
1 Year Success Rate
6/9 ratings generated profit
1 Year Average Return
+208.11%
reiterated a buy rating 13 days ago
Copying Vernon Bernardino's trades and holding each position for 1 Year would result in 66.67% of your transactions generating a profit, with an average return of +208.11% per trade.
---